Impax Laboratories Inc (NASDAQ:IPXL)

19.60
Delayed Data
As of Feb 16
 +0.20 / +1.03%
Today’s Change
7.75
Today|||52-Week Range
25.70
+17.72%
Year-to-Date
Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles
Feb 16 / TheStreet.com - Paid Partner Content
Lee Ainslie Boosts 2 Health Care Positions
Feb 12 / GuruFocus News - Paid Partner Content

Today’s Trading

Previous close19.40
Today’s open19.35
Day’s range19.20 - 20.20
Volume1,113,921
Average volume (3 months)1,257,318
Market cap$1.5B
Data as of 4:00pm ET, 02/16/2018

Growth & Valuation

Earnings growth (last year)-1,327.78%
Earnings growth (this year)-45.29%
Earnings growth (next 5 years)+12.91%
Revenue growth (last year)-4.19%
P/E ratioNM
Price/Sales1.14
Price/Book2.32

Competitors

 Today’s
change
Today’s
% change
LXRXLexicon Pharmaceutic...-0.07-0.88%
RGENRepligen Corp-0.11-0.33%
ARRYArray Biopharma Inc-0.27-1.57%
EBSEmergent BioSolution...+0.79+1.61%
Data as of 4:02pm ET, 02/16/2018

Financials

Next reporting dateMarch 1, 2018
EPS forecast (this quarter)$0.11
Annual revenue (last year)$824.4M
Annual profit (last year)-$472.0M
Net profit margin-57.26%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President, Chief Executive Officer &
Director
Paul M. Bisaro
Senior Vice President-
Global Operations
Andrew Schaschl
Corporate headquarters
Hayward, California

Forecasts